Bedrijfsoverzicht
Atrium Therapeutics, Inc. is a biopharmaceutical enterprise dedicated to the development and delivery of ribonucleic acid (RNA) therapeutics specifically targeting the heart to improve outcomes for patients suffering from cardiomyopathies. Operating within the healthcare sector and the biotechnology industry, the company leverages advanced molecular biology to create novel treatments that address unmet medical needs in cardiovascular care. The entity operates with a market capitalization of $197.20M and reported annual revenue of $18.62M over the trailing twelve-month period, while the specific employee count is not disclosed in public filings. These valuation and revenue figures position the company as a mid-stage biotechnology firm, indicating that it is still in the critical phase of product development where capital expenditure is high relative to current sales, rather than a mature revenue-generating enterprise.
Financiële gezondheid
The company reported revenue of $18.62M for the trailing twelve months, yet this generated a net income of -$49,501,000 and an EBITDA of -$49,308,000, revealing a substantial gap between top-line performance and bottom-line profitability. This significant divergence indicates a cost structure dominated by research and development expenses and operational overheads that far exceed current revenue streams, which is typical for early-stage biotechnology companies. Free cash flow stands at -$11,653,375, signaling that the company is burning cash to fund its operations and development pipeline rather than generating surplus liquidity for dividends or buybacks. The gross margin is reported at -137.8%, the operating margin at -3387.9%, and the profit margin at -265.9%; these deeply negative figures reflect the high cost of goods sold and operating expenses relative to the modest sales volume. Total debt amounts to $3.67M, while the cash balance is not available in the provided data, and the debt-to-equity ratio is not applicable, suggesting that leverage is not a primary driver of the company's current financial profile. The current ratio is 0.07, which indicates severe short-term liquidity constraints, meaning the company's current assets are insufficient to cover its current liabilities without external financing. Return on equity is not applicable, while return on assets stands at -399.2%, demonstrating that management is currently generating significant losses on the asset base employed.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not applicable due to negative earnings, whereas the forward P/E is listed at -3.15, implying that the market prices the stock based on anticipated future losses rather than current profitability. The price-to-book ratio is -3.14, a metric that is mathematically distorted by the company's negative book value and suggests that traditional valuation comparisons to tangible assets are not meaningful at this stage. The price-to-sales ratio is 10.59, and the EV/EBITDA is not applicable; these alternative metrics indicate that investors are valuing the company almost exclusively on its potential intellectual property and pipeline value rather than historical sales performance or earnings power. Over the past year, the stock price fluctuated between a low of $11.95 and a high of $16.77, providing a reference range for recent market sentiment. Without a specific current share price provided in the facts, the exact percentage distance from the 52-week high cannot be calculated, but the narrow trading range suggests limited price volatility in the short term. The beta value is not applicable, meaning that the stock's sensitivity to broader market movements cannot be quantified using historical volatility data relative to the market index.
Growth & Income
Revenue growth year-over-year is -71.1%, while earnings growth year-over-year is not applicable, indicating a sharp contraction in sales and the absence of a profitable earnings trajectory to analyze. The negative revenue growth suggests the company is still in a phase of building a commercial footprint or facing headwinds in commercializing its RNA therapy candidates rather than expanding its market share. As a non-dividend payer, the company distributes 0.0% in dividends, meaning that any available capital is retained and reinvested into research, development, and operational scaling rather than being distributed to shareholders. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, reflecting a high-risk, high-reward investment thesis typical of biotechnology firms focused on pipeline progression.